Femasys Inc. announced the appointment of a new board member, Wendy Perrow. Ms. Perrow brings decades of experience in the life sciences industry related to fundraising, global product launches and corporate strategy. Additionally, Femasys announced that William Witte, a board member since 2017 has resigned.

Ms. Perrow brings a proven record of company-building and fundraising, in addition to corporate strategy, business and product development, regulatory, manufacturing and marketing in the life sciences. Most recently, Ms. Perrow was the chief executive officer of AsclepiX Therapeutics Inc., an early-stage biotechnology company developing novel peptide therapeutics for indications in retinal diseases and oncology. She also served as an AsclepiX board member.

Prior to this, Ms. Perrow was the chief executive officer of Alba Therapeutics Inc., a clinical-stage biotechnology company developing novel therapeutics for autoimmune and gastrointestinal diseases. Throughout her career, Ms. Perrow has led the creation of companies focused on ophthalmology and oncology, and she has launched world-renowned products in cholesterol, vaccines, and hypertension yielding multi-billion dollars in sales, as well as closed a multi-million dollar out-licensing deal for a first-of-its kind phase 2 asset. Ms. Perrow additionally has diverse global business experience working with the U.S., European, Pan-Asian and Latin American markets.

Ms. Perrow will hold office as a Class II director for a term expiring at the annual meeting following the year ending December 31, 2022 and will serve on the Compensation Committee of the Company. In addition, effective January 19, 2022, Anne Morrisey, a current member of the Board of Directors, was appointed by the Board of Directors to serve on the Nominating and Governance Committee.